



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ustekinumab

Cat. No.:	HY-P9909
CAS No.:	815610-63-0
Molecular Weight:	145625.97
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.	
IC ₅₀ & Target	IL-12	IL-23
In Vitro	Ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells ^[1] . Ustekinumab is a human IgG1 kappa (κ) monoclonal antibody against the IL-12/IL-23 p40 subunit that prevents its interaction with IL-12Rβ1, thereby blocking subsequent signaling. The FcRn affinities at pH 6.0 fell in a narrow range for all 11 antibodies. The equilibrium dissociation constant (K _D) is calculated relative to Ustekinumab (Ustekinumab=1.0) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

PROTOCOL

Cell Assay ^[2]	HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200 μg/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 min at 37°C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
---------------------------	--

CUSTOMER VALIDATION

- Nat Immunol. 2021 Sep;22(9):1107-1117.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Montepaone M, et al. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13.

[2]. Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA